Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 juil. 2013 08h00 HE | Source: Merrimack Pharmaceuticals

Merrimack Initiates Phase 2 Clinical Study of MM-111 in Advanced Gastroesophageal Cancers

CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific...
17 juil. 2013 16h15 HE | Source: Merrimack Pharmaceuticals

Merrimack Closes Concurrent Sale of 5,750,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes

CAMBRIDGE, Mass., July 17, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the closing of its sale of 5,750,000 shares of its common stock at a price to the...
11 juil. 2013 23h52 HE | Source: Merrimack Pharmaceuticals

Merrimack Prices Concurrent Public Offerings of 5,000,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes

CAMBRIDGE, Mass., July 11, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it has priced concurrent public offerings of 5,000,000 shares of its common stock...
10 juil. 2013 16h01 HE | Source: Merrimack Pharmaceuticals

Merrimack Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes

CAMBRIDGE, Mass., July 10, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced its intention to offer, subject to market and other conditions, $50 million of its...
06 juin 2013 12h07 HE | Source: Merrimack Pharmaceuticals

Merrimack to Present at the Goldman Sachs 34th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that William Sullivan, CFO, is scheduled to present at the Goldman Sachs 34th Annual...
04 juin 2013 09h00 HE | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors

CAMBRIDGE, Mass., June 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be...
23 mai 2013 08h00 HE | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer

CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical...
13 mai 2013 10h00 HE | Source: Merrimack Pharmaceuticals

Merrimack Reports First Quarter 2013 Financial Results

CAMBRIDGE, Mass., May 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
02 mai 2013 08h00 HE | Source: Merrimack Pharmaceuticals

Merrimack to Present at Multiple Investor Conferences This Spring

CAMBRIDGE, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that their management team is scheduled to present at multiple investor conferences this...
30 avr. 2013 10h00 HE | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Timing of First Quarter 2013 Investor Conference Call

CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its First Quarter 2013 Investor Conference Call and...

Page précédente

Page suivante